Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
Although both MRD and karyotype are powerful determinants of
outcome in childhood ALL, few studies have examined the kinetics of
MRD clearance by cytogenetics. In ALL2003, patients are stratified
by NCI criteria to a three or four drug induction. MRD is assessed at
day 29 and week 11 using a standardised and quality controlled RQPCR
of 21patient specific immunoglobulin or T-cell receptor
rearrangements. MRD risk groups were defined as: (1) High risk
MRD410-4 at day 29 (HR); (2) Low risk MRD negative or o10-4 at
day 29 and negative at week 11 (LR); or (3) MRD indeterminate risk.
Among 1000 patients entered into the trial, 98% were eligible for
these analyses, 94% had a successful cytogenetics and 57% were
assigned to a clinically relevant MRD groups. Among these latter 555
patients, 54% were MRD-HR whereas 45% were MRD-LR. Collectively,
patients with high-risk cytogenetics ‘t(9;22), o40 chromosomes,
11q23/MLL, t(17;19) and iAMP21’ were more likely to be MRDHR
‘83% vs 52%, P50.003’. Patients with ETV6-RUNX1 fusion were
less likely to be MRD-HR ‘28% vs 63%, Po0.001’ whereas high
hyperdiploid patients were more likely ‘64% vs 49%, P50.002’.
However, excluding ETV6-RUNX1 patients from the latter analysis
revealed that high hyperdiploid patients were as likely to be MRDHR
as other ETV6-RUNX1 negative patients. T-ALL patients were
also more likely to be MRD-HR compared to BCP-ALL patients ‘70%
vs 52%, P50.022’. In particular, 9/10 patients with t(5;14)/TLX3-
BCL11B fusion and 6/6 patients with SIL-TAL1 fusion were MRD-HR.
In conclusion, we have clearly demonstrated that MRD status varies
by cytogenetic subgroup with ETV6-RUNX1 patients having the
fastest MRD clearance rate. Despite the good prognosis associated
with high hyperdiploidy, these patients were as likely to be MRD-HR
as other standard risk patients. Longer follow-up is required to
determine the clinical significance of this finding.
children, minimal residual disease, disease, time
pp. 2
Moorman, A.V.
af5027f3-4927-4e62-b1be-ac4bdcf6cd8f
Richards, S.M.
f332bcb7-385f-42df-84a1-b98a1e4b4c1d
Hancock, J.P.
39bcde5f-e02c-4304-9064-83ef424ed35b
Mitchell, C.D.
6ed5bf04-46f6-4c29-a638-5fcc901b2f7f
Vora, A.J.
00604d4f-ebe3-4682-8d5d-5be49e9daf32
Harrison, C.J.
9c9f6b47-8bfc-49dd-b156-74539b170291
Goulden, N.J.
bda9ee20-7d19-46d4-bcba-d07f1c98345f
31 March 2008
Moorman, A.V.
af5027f3-4927-4e62-b1be-ac4bdcf6cd8f
Richards, S.M.
f332bcb7-385f-42df-84a1-b98a1e4b4c1d
Hancock, J.P.
39bcde5f-e02c-4304-9064-83ef424ed35b
Mitchell, C.D.
6ed5bf04-46f6-4c29-a638-5fcc901b2f7f
Vora, A.J.
00604d4f-ebe3-4682-8d5d-5be49e9daf32
Harrison, C.J.
9c9f6b47-8bfc-49dd-b156-74539b170291
Goulden, N.J.
bda9ee20-7d19-46d4-bcba-d07f1c98345f
Moorman, A.V., Richards, S.M., Hancock, J.P., Mitchell, C.D., Vora, A.J., Harrison, C.J. and Goulden, N.J.
(2008)
Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL).
British Journal of Haematology, 141 (Supplement 1), .
(doi:10.1111/j.1365-2141.2008.07061.x).
Abstract
Although both MRD and karyotype are powerful determinants of
outcome in childhood ALL, few studies have examined the kinetics of
MRD clearance by cytogenetics. In ALL2003, patients are stratified
by NCI criteria to a three or four drug induction. MRD is assessed at
day 29 and week 11 using a standardised and quality controlled RQPCR
of 21patient specific immunoglobulin or T-cell receptor
rearrangements. MRD risk groups were defined as: (1) High risk
MRD410-4 at day 29 (HR); (2) Low risk MRD negative or o10-4 at
day 29 and negative at week 11 (LR); or (3) MRD indeterminate risk.
Among 1000 patients entered into the trial, 98% were eligible for
these analyses, 94% had a successful cytogenetics and 57% were
assigned to a clinically relevant MRD groups. Among these latter 555
patients, 54% were MRD-HR whereas 45% were MRD-LR. Collectively,
patients with high-risk cytogenetics ‘t(9;22), o40 chromosomes,
11q23/MLL, t(17;19) and iAMP21’ were more likely to be MRDHR
‘83% vs 52%, P50.003’. Patients with ETV6-RUNX1 fusion were
less likely to be MRD-HR ‘28% vs 63%, Po0.001’ whereas high
hyperdiploid patients were more likely ‘64% vs 49%, P50.002’.
However, excluding ETV6-RUNX1 patients from the latter analysis
revealed that high hyperdiploid patients were as likely to be MRDHR
as other ETV6-RUNX1 negative patients. T-ALL patients were
also more likely to be MRD-HR compared to BCP-ALL patients ‘70%
vs 52%, P50.022’. In particular, 9/10 patients with t(5;14)/TLX3-
BCL11B fusion and 6/6 patients with SIL-TAL1 fusion were MRD-HR.
In conclusion, we have clearly demonstrated that MRD status varies
by cytogenetic subgroup with ETV6-RUNX1 patients having the
fastest MRD clearance rate. Despite the good prognosis associated
with high hyperdiploidy, these patients were as likely to be MRD-HR
as other standard risk patients. Longer follow-up is required to
determine the clinical significance of this finding.
This record has no associated files available for download.
More information
Published date: 31 March 2008
Additional Information:
Free Communications: Paediatric Malignancy 1 (p 1-121)
Keywords:
children, minimal residual disease, disease, time
Identifiers
Local EPrints ID: 62862
URI: http://eprints.soton.ac.uk/id/eprint/62862
ISSN: 0007-1048
PURE UUID: d3fd9440-494d-409a-9d09-06e75f5da037
Catalogue record
Date deposited: 07 Oct 2008
Last modified: 15 Mar 2024 11:33
Export record
Altmetrics
Contributors
Author:
A.V. Moorman
Author:
S.M. Richards
Author:
J.P. Hancock
Author:
C.D. Mitchell
Author:
A.J. Vora
Author:
C.J. Harrison
Author:
N.J. Goulden
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics